Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting and Submission of Unaudited Standalone and Consolidated Financial Results

Audit Opinion:

The limited review reports for both standalone and consolidated financial results were submitted with unmodified opinions (free from any qualifications).

Auditor’s Comment:

For the consolidated results, the auditor noted that they did not review the interim financial results of 6 subsidiaries included in the Statement. These subsidiaries reflected total revenues of ₹129.45 Crores, total net profit after tax of ₹16.09 Crores and total comprehensive income of ₹16.03 Crores for the quarter. The Statement also includes the Group's share of net loss after tax of ₹0.40 Crores and total comprehensive loss of ₹0.40 Crores for the quarter in respect of 1 joint venture, whose interim financial results were not reviewed by the auditor. The conclusion for these entities is based solely on the review reports of other auditors. The auditor's conclusion was not modified in respect of this matter.

Key Financial Highlights [Rs in Crore]:

Consolidated Results:

Revenue from Operations: ₹873.25 (Q1 FY27) vs ₹773.00 (Q1 FY26) [12.97% YoY growth]

  • Sale of products: ₹869.03
  • Other operating income: ₹4.22

Total Income: ₹875.64

  • Other income: ₹2.39

Profit before tax: ₹179.49

Tax Expense: ₹36.17

  • Current tax: ₹31.10
  • Deferred tax: ₹5.07

Net Profit: ₹143.32 (Q1 FY27) vs ₹125.10 (Q1 FY26) [14.56% YoY growth]

  • Attributable to owners of the Company: ₹142.39
  • Attributable to non-controlling interest: ₹0.93

EPS (not annualised):

  • Basic: ₹10.28
  • Diluted: ₹10.26

Other Equity: ₹3,888.82 (as of March 31, 2026)

Standalone Results:

Revenue from Operations: ₹443.99 (Q1 FY27)

  • Other operating income: ₹10.18

Total Income: ₹470.37

  • Other income: ₹26.38

Profit before tax: ₹64.14

Tax Expense: ₹15.84

  • Current tax: ₹10.23
  • Deferred tax: ₹5.61

Net Profit: ₹48.30

EPS (not annualised):

  • Basic: ₹3.49
  • Diluted: ₹3.48

Other Equity: ₹3,181.61 (as of March 31, 2026)

Segment-wise Performance:

The company is primarily engaged in one business segment namely "Pharmaceuticals" as determined by the chief operating decision maker in accordance with Ind AS 108.

Corporate Actions:

The Board of Directors had declared an interim dividend of ₹7.21 (at the rate of 721%) per equity share of the face value of ₹1 each for the financial year 2026-27 at its meeting held on May 20, 2026.

The company issued and allotted 35,602 ordinary shares of ₹1 each under the Company's Employee Stock Option Scheme 2021 during the quarter ended June 30, 2026.

Other Significant Information:

Labour Code Impact: Effective from November 21, 2025, the Government of India consolidated multiple labour legislations into four 'New Labour Codes'. This resulted in an increase in gratuity liability and leave liability arising out of past service cost by ₹17.24 Crores (consolidated) and ₹14.67 Crores (standalone) primarily due to change in definition of "wages". This was presented as an "Exceptional Item" in the financial results for the year ended March 31, 2026.

Tax Rate Change: In accordance with Ind AS 12, deferred tax assets and liabilities were remeasured using tax rates enacted through the Income Tax Act 2025 as amended by Finance Act 2026. This resulted in a deferred tax credit of ₹150 Crores (consolidated) and ₹18 Crores (standalone) being recognized in the statement of profit and loss for the quarter and year ended March 31, 2026.

Acquisition: During the quarter and year ended March 31, 2026, the company completed acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for a consideration of ₹50 Crores on a slump sale basis. The company is in the process of making final determination of fair values for purchase price allocation.

Scheme of Arrangement: During the year ended March 31, 2026, Eris Therapeutics Limited proposed a scheme whereby the "Domestic Business" of Eris Oaknet Healthcare Private Limited shall get vested into ETL and Aprica Healthcare Limited would be amalgamated with ETL. The Scheme is subject to necessary statutory and regulatory approvals.

Additional Regulatory Ratios (Consolidated):

  • Debt-Equity Ratio: 0.64 (June 30, 2026) vs 0.74 (June 30, 2025)
  • Debt Service Coverage Ratio: 2.75 (June 30, 2026) vs 2.60 (June 30, 2025)
  • Interest Service Coverage Ratio: 4.86 (June 30, 2026) vs 4.29 (June 30, 2025)
  • Net Worth: ₹3,944.22 (June 30, 2026) vs ₹3,399.10 (June 30, 2025)
  • Current Ratio: 0.60 (June 30, 2026) vs 0.93 (June 30, 2025)
  • Operating Margin: 25.94% (June 30, 2026) vs 27.02% (June 30, 2025)
  • Net Profit Margin: 16.41% (June 30, 2026) vs 16.18% (June 30, 2025)

Additional Regulatory Ratios (Standalone):

  • Debt-Equity Ratio: 0.62 (June 30, 2026) vs 0.89 (June 30, 2025)
  • Debt Service Coverage Ratio: 1.61 (June 30, 2026) vs 1.52 (June 30, 2025)
  • Interest Service Coverage Ratio: 2.52 (June 30, 2026) vs 1.77 (June 30, 2025)
  • Net Worth: ₹3,148.45 (June 30, 2026) vs ₹2,514.90 (June 30, 2025)
  • Current Ratio: 0.47 (June 30, 2026) vs 0.63 (June 30, 2025)
  • Operating Margin: 23.94% (June 30, 2026) vs 34.81% (June 30, 2025)
  • Net Profit Margin: 10.88% (June 30, 2026) vs 17.28% (June 30, 2025)

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad - 380054

Auditor:

Walker Chandiok & Co LLP, Chartered Accountants

Company Officials:

  • Milind Talegaonkar, Company Secretary & Compliance Officer
  • Ami Bakshi, Chairman and Managing Director